Skip to content
mystocks Logo
Synchron

Synchron

Live Now
Neurotech
Primary Allocation

Implied Valuation

$995.0M

Price per Share

$15.12

AI Investment Thesis

VALUATION TRAJECTORY
Registry audit of capital round evolution.
Program Mandate

Synchron is a pioneer in the field of brain-computer interfaces (BCIs). Their flagship product, the Stentrode, is an endovascular BCI that can be implanted without open brain surgery. It is designed to help patients with severe paralysis control digital devices using their thoughts. This funding will support FDA trials and commercialization efforts.

Deployment Terms
Vehicle StructureAugment Collective SPV
Carried Interest0%
Platform Setup Fee2%
Management Fee0% p.a.
Ownership TypeIndirect
Funding History
RoundDateAmountValuation
Series C
Dec 2022$75.0M$0.3B
Series B
Jun 2021$40.0M$0.1B
Current Offering
Live Now-$15.12 / Share

Private market risk — capital at risk

Private market and pre-IPO investments are high-risk and illiquid. You may lose your entire investment, there is no public market in which to sell your holding, and any return may take years to materialise — a future listing is never guaranteed. This page is general information, not financial advice or an offer to sell securities. Read our risk disclosure before investing.